KNS-366 is under clinical development by Kynos Therapeutics and currently in Phase I for Pancreatitis. According to GlobalData, Phase I drugs for Pancreatitis does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the KNS-366 LoA Report. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

KNS-366 overview

KNS-366 is under development for the treatment of acute pancreatitis. The drug candidate act by targeting kynurenine 3-monooxygenase. The drug candidate is a benzisoxazole derivatives. It is administrated by intravenous route.

Kynos Therapeutics overview

Kynos Therapeutics is a biotechnology company which is engaged in the developing new medicines for critical illness, chronic inflammatory and cancer diseases. The company is headquartered in Edinburgh, Scotland, the UK.

For a complete picture of KNS-366’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.